Objectives. To investigate the effects of the active metabolite of leflunomide, A77 1726, on fibroblast-like synoviocytes. In rheumatoid arthritis (RA) synoviocytes participate in tissue destruction by producing metalloproteinases (MMP), prostaglandin E 2 (PGE 2 ) and interleukin (IL) 6, which are involved in extracellular matrix degradation, resorption of the mineral phase and osteoclast-mediated bone resorption. Methods. Human synoviocytes were stimulated with IL-1a or tumour necrosis factor a (TNF-a) in the presence of A77 1726. Culture supernatants were analysed for production of interstitial collagenase (MMP-1), tissue-inhibitor of metalloproteinases 1 (TIMP-1), PGE 2 and IL-6. Total RNA was isolated and analysed for steady-state levels of MMP-1, cyclooxygenase-2 (COX-2) and IL-6 mRNA. Results. A77 1726 inhibited the production of PGE 2 in synoviocytes activated by TNF-a and IL-1a with median inhibitory concentrations (IC 50 ) of 7 and 3 mM respectively. In contrast, MMP-1 and IL-6 production was inhibited at high A77 1726 concentrations (> 10 mM), whereas TIMP-1 was not affected. The inhibition of MMP-1 and IL-6 production was due to the known inhibitory effect of A77 1726 on pyrimidine synthesis, as it was reversed by the addition of uridine. This did not apply to PGE 2 production, which was inhibited via direct action of A77 1726 on COX-2, as shown by the increasing amount of substrate (arachidonic acid) in the culture medium. Conclusion. This study shows that some of the beneficial effect of leflunomide in RA patients may be due to the inhibition of PGE 2 , IL-6 and MMP-1 production in synoviocytes. This effect, coupled with its multiple inhibitory effects on T lymphocyte functions, might account for the significant reduction in the rate of disease progression in RA patients treated with leflunomide.
Rheumatoid arthritis (RA) is characterized by the thickening of synovial tissue and the destruction of joint structure. The inflamed synovium thickens due to the local proliferation of synovial cells and infiltration of inflammatory cells such as lymphocytes and monocyte-macrophages w1x. We have established that contact-mediated signalling of monocytes by stimulated T lymphocytes is a potent mechanism which might play a part in the persistence of chronic inflammation, mainly in that it induces the production of large amounts of the proinflammatory cytokines tumour necrosis factor a (TNF-a) and interleukin (IL) 1b w2x. IL-1 and TNF-a are potent inducers of metalloproteinases (MMP), prostaglandin E 2 (PGE 2 ) and IL-6 in synoviocytes w3x. The activity of MMP is specifically controlled by tissue inhibitors of metalloproteinases (TIMP) w4x, whose production is increased by IL-6 w5x. Numerous observations support the premises that in RA the resorption of the mineral phase is dependent on PGE 2 , the extracellular matrix degradation is mediated by proteolytic enzymes such as MMP, and the resorption of periarticular bones is triggered by IL-6-stimulated osteoclasts w6x. Together, these mechanisms lead to tissue destruction and eventually invalidity in patients w1, 7x.
Leflunomide (Arawa 2 ) has been approved by the Food and Drug Administration for treatment of RA w8x. In vivo (in the cell), leflunomide is rapidly converted into its active metabolite A77 1726 w9x. Although the precise mode of action of leflunomide in vivo is still elusive, in vitro A77 1726 reversibly inhibits dihydroorotate dehydrogenase (DHODH), the rate-limiting step in the de novo synthesis of pyrimidines w10-12x. Indeed, most of the effects of A77 1726 can be reversed by supplying the product of DHODH activity, i.e. uridine, to target cells. Leflunomide is a potent non-cytotoxic inhibitor of the proliferation of stimulated B and T lymphocytes in vitro, it is effective in several rodent models of autoimmune diseases, and it prolongs graft survival in animals w9, 13x. The latter effects have drawn attention to the mechanisms of action of leflunomide in immune cells, mainly T cells, in which it also blocks TNF-mediated cellular responses by inhibiting nuclear factor-kB (NFkB), a mechanism that depends on pyrimidine biosynthesis w14, 15x. We showed previously that A77 1726 inhibited the expression of monocyteactivating factor at the surface of T lymphocytes. This in turn decreased the activation of monocytemacrophages, thus inhibiting the production of IL-1b and MMP by monocyte-macrophages w16x. In this study, we address the question of the effect of A77 1726 on the production of PGE 2 , IL-6 and MMP-1 in synoviocytes isolated from RA patients.
Materials and methods

Materials and reagents
The active metabolite of leflunomide, A771726, the kind gift of Dr M. Herrmann (Aventis, Wiesbaden, Germany), was made up as a 2 mM solution in water. Dulbecco's modified Eagle's minimal essential medium (DMEM), phosphatebuffered saline without Ca 2+ and Mg 2+ (PBS), fetal calf serum (FCS), penicillin, streptomycin, L-glutamine and TRIzol 2 reagent were purchased from Gibco (Paisley, UK), and arachidonic acid (AA) and uridine were purchased from Sigma Fine Chemicals (St Louis, MO, USA). All other reagents were of analytical grade or better. Human recombinant IL-1a and TNF-a were obtained from Biogen (Geneva, Switzerland) and Synergen (Boulder, CO, USA), respectively. 
Synoviocyte cultures
Results
A77 1726 inhibits PGE 2 , IL-6 and MMP-1 but not TIMP-1 production in synoviocytes
To determine whether A77 1726 affects the production of PGE 2 , IL-6, MMP-1 and TIMP-1, isolated synoviocytes were activated by an optimal concentration of TNF-a (10 nguml) or IL-1a (250 pguml) in the presence or absence of A77 1726. In human synoviocytes, which did not produce significant amounts of PGE 2 in the absence of stimulus, TNF-a and IL-1a induced the production of 190"76 and 291"130 nguml PGE 2 respectively (Fig. 1A) . PGE 2 production was completely abolished in the presence of 10 24 M A77 1726. Synoviocytes constitutively produced MMP-1 (1.9"1.6 mguml, n=5) and its inhibitor TIMP-1 (3.0"1.9 mguml). Depending on the synoviocyte donorupreparation, TNF-a and IL-1a increased MMP-1 production to 3.8"1.7 and 3.1"1.5 mguml respectively, and the induced but not the basal production of MMP-1 was inhibited by 10 24 M A77 1726 (Fig. 1B) . In contrast, TIMP-1 production was neither increased by TNF-a or IL-1a nor affected by A77 1726 (Fig. 1C ). IL-6 production by synoviocytes was marked in the absence of stimulus, reaching 7"5 nguml (Fig. 1D ). This basal production was increased by IL-1a and TNF-a to 346"100 and 129"78 nguml respectively. In the presence of A77 1726, the IL-6 production induced by IL-1a and TNF-a was inhibited by 47 and 63% respectively (Fig. 1D) .
To ascertain whether the inhibitory effect of A77 1726 on PGE 2 , IL-6 and MMP-1 production would occur at concentrations possibly reached in treated patients, the
inhibitory effect of serial concentrations of A77 1726 was assessed. A77 1726 diminished PGE 2 production by synoviocytes in a dose-dependent way; PGE 2 production was abolished at 10 24 M A77 1726 and inhibited by 100 and 99% upon stimulation by TNF-a and IL-1a respectively ( Fig. 2A and B) . The apparent median inhibitory concentration (IC 50 ) was 7 and 3 mM A77 1726 when synoviocytes were stimulated by TNF-a and IL-1a respectively. In contrast, the induction of MMP-1 production was inhibited at high A77 1726 concentrations only, and no inhibition was observed at concentrations < 5310 25 M A77 1726 ( Fig. 2C and D) . Similarly, the induced production of IL-6 was only inhibited by concentrations > 5310 25 M A77 1726 ( Fig. 2E and F) . Confirming results shown in Fig. 1 , TIMP-1 production was not affected by A77 1726 (Fig. 2G and 2H) , demonstrating that the marked inhibition of cytokineinduced production of PGE 2 , IL-6 and MMP-1 at high A77 1726 concentration was not due to a putative cytotoxic effect of the drug.
A77 1726 inhibited PGE 2 , MMP-1 and IL-6 through different mechanisms
In order to assess whether the inhibition of PGE 2 , MMP-1 and IL-6 production was due to the welldescribed in vitro inhibition of pyrimidine synthesis by A77 1726, uridine was used to reverse the inhibitory effect of A77 1726. In contrast with the inhibition of MMP-1 and IL-6 production that was completely reversed by uridine (Fig. 3) , the inhibition of PGE 2 production by A77 1726 was not reversed by either 50 mM (data not shown) or 200 mM uridine (Fig. 3) . This suggests that the inhibition of MMP-1 and IL-6 production was due to the inhibition of DHODH, i.e. the inhibition of pyrimidine synthesis, another mechanism involved in the inhibition of PGE 2 production.
Because A77 1726 has been reported to inhibit the activity of cyclooxygenase (COX) 2 directly w22, 23x, the inhibition of PGE 2 production by A77 1726 was assessed in the presence of an excess of the enzyme substrate AA. As shown in Fig. 4A and B, AA (30 mM) 
did not induce a detectable amount of PGE 2 , suggesting that COX-1 expression by synoviocytes was poor. AA increased the production of PGE 2 induced by IL-1a and TNF-a, which reached 743"221 and 406"210 nguml respectively. AA shifted the IC 50 to 20 mM A77 1726 ( Fig. 4A and B) , implying that the inhibitor was displaced from the enzyme and consequently that A77 1726 interacted directly with COX-2. In the presence of AA, neither the production of MMP-1 nor its inhibition by A77 1726 was affected (not shown). Upon synoviocyte stimulation by IL-1a and TNF-a, AA increased basal IL-6 production slightly (1.3-and 1.7-fold respectively, to 340"26 and 100"13 nguml). Although AA did not reverse the inhibition by A77 1726 of IL-6 production induced by IL-1a (Fig. 4C) , it partially reversed the inhibition when synoviocytes were stimulated by TNF-a (Fig. 4D ). This suggests that PGE 2 might enhance cytokine-induced IL-6 production, a phenomenon that was more pronounced, i.e. detectable, when cytokine stimulation was low. Indeed, the production of IL-6 induced by TNF-a was three times lower than that induced by IL-1a, suggesting that IL-1a overcame the enhancing effect of PGE 2 on IL-6 production. This was confirmed by the use of indomethacin, which inhibits the production of PGE 2 .
Indomethacin abolished the production of PGE 2 induced by both IL-1a and TNF-a (Fig. 5A ). Because MMP-1 production was not affected, its inhibition by Fig. 1 . In the absence of A77 1726, PGE 2 production was 743"221 and 140"83 nguml in the presence of IL-1a plus AA and of IL-1a alone, respectively, and 406"210 and 76"13 nguml in the presence of TNF-a plus AA and of TNF-a alone, respectively. In the absence of inhibitor, IL-6 production was 340"26 and 260"22 nguml in the presence of IL-1a plus AA and of IL-1a alone, respectively, and 100"13 and 60"6 nguml in the presence of TNF-a plus AA and of TNF-a alone, respectively. concentration in the medium (Fig. 5B) . However, the specific inhibition of PGE 2 production by indomethacin decreased IL-6 production by 20 and 42% when synoviocytes were stimulated by IL-1a and TNF-a respectively, demonstrating that the production of IL-6 due to endogenously produced PGE 2 was higher when cells were stimulated by TNF-a than by IL-1a.
To confirm that different mechanisms were involved in the inhibition of PGE 2 , MMP-1 and IL-6 in synoviocytes, the effect of A77 1726 on steady-state levels of mRNAs for COX-2, MMP-1 and IL-6 was assessed by either Northern blot or RNase protection analysis. COX-2 mRNA was not expressed in synoviocytes, whether unstimulated or cultured in the presence of AA (Fig. 6A and B) . Upon stimulation for 3 h by IL-1a or TNF-a, COX-2 mRNA was expressed. Levels of MMP-1 mRNA were high in unstimulated synoviocytes, and 2-to 2.5-fold increase was observed in the presence of cytokines ( Fig. 6C and F) . However, in the presence of A77 1726, AA, or both, there were no changes in the steady-state level of either COX-2 or MMP-1 mRNA, as shown by Northern blot analysis (Fig. 6A-C) . Similarly, after 15 h of incubation the steady-state level of MMP-1 mRNA was not affected by A77 1726, uridine, or both, as shown by RNase protection assay (Fig. 6D and F ). This contrasted with the fact that MMP-1 production induced by cytokines was indeed inhibited by A77 1726 (Figs 1  and 2 ) and that uridine reversed this inhibition (Fig. 4 ). The steady-state level of IL-6 mRNA was inhibited by A77 1726, an effect that was reversed by uridine ( Fig. 6D and E) . This confirms that A77 1726 inhibited IL-6 production through the inhibition of DHODH, i.e. the inhibition of pyrimidine synthesis.
Discussion
The salient result of this study is that leflunomide modulates the production of destructive factors by synoviocytes. Indeed, the active metabolite of leflunomide, A77 1726, inhibits PGE 2 , IL-6 and MMP-1 production in synoviocytes. Although the inhibition of MMP-1 and IL-6 production only occurred at high A77 1726 concentrations, PGE 2 production was inhibited by A77 1726 with an IC 50 <10 mM when either IL-1a or TNF-a was used as a stimulus. This effect was not reversed by uridine, contrary to other inhibitory activities of A77 1726 that have been described w9, 15x, which have an IC 50 in the same range. However, the inhibition of MMP-1 and IL-6 production was fully reversed by uridine, demonstrating that the inhibition of MMP-1 and IL-6 expression was due to the blockade of pyrimidine synthesis. The inhibition of MMP-1 and IL-6 production was observed in the presence of 05 310 25 M A77 1726, roughly equal to the maximal plasma concentration in treated patients, i.e. around 50 mM w24x. This suggests that part of the beneficial effects of A77 1726 in RA patients might be due to the inhibition of PGE 2 , MMP-1 and IL-6 production in synoviocytes.
High concentrations of A77 1726 are required to inhibit the induced production of MMP-1 and IL-6. However, even at these high drug concentrations, the production of TIMP-1 was not affected by A77 1726, showing that high levels of A77 1726 did not display cytotoxicity towards synoviocytes. Furthermore, from the premise that TIMP-1 production remained unchanged upon A77 1726 treatment, it follows that the drug tends to favour factors that counteract the enzymatic Effects of leflunomide on synoviocytes 93 Effects of leflunomide on synoviocytes 93 degradative processes. This is reminiscent of previous results we obtained about the effect of A77 1726 on the expression of monocyte-stimulating factors on the surface of activated T lymphocytes w16x. Indeed, in that study we showed that in the presence of 10 25 M A77 1726 the molar ratios of IL-1 receptor agonistuIL-1b and TIMP-1uMMP-1 produced by the monocytic cells were increased around 4-and 2-fold, respectively. This demonstrated that in the T cellumonocyte-macrophage system also, A77 1726 tends to favour the inhibition of proinflammatory and matrix-destructive factors over that of anti-inflammatory factors and metalloproteinase inhibitors, thus interfering with both inflammation and tissue destruction.
A77 1726 inhibited the activity of COX-2 directly. Indeed, an excess of exogenous COX-2 substrate (AA) increased the cytokine-induced production of PGE 2 in the absence of A77 1726 and increased the IC 50 of A77 1726 2-to 6-fold. The direct inhibition of COX-2 by A77 1726 has been described in other cellular systems. A77 1726 inhibits the activity of COX-1 and -2 isolated from sheep, although with an IC 50 of 742 and 2766 mM respectively, suggesting that A77 1726 is a weak inhibitor of PGE 2 synthesis w22x. This low inhibitory potency was attributed in part to the premise that A77 1726 displays extremely high levels of binding to serum proteins w25x. More recently, A77 1726 was shown to inhibit COX-2 activity in the presence of 10% FCS in two cell lines, J774.2 murine macrophages and A549 human epithelial cancer cells, with IC 50 values comparable to those observed here, i.e. in the micromolar range w23x. Although A77 1726 has been shown to inhibit PGE 2 production directly in several types of cell, this is the first observation of such inhibition occurring in synoviocytes, which are primarily involved in tissue degradation processes in RA. A77 1726 has been shown to inhibit both COX-1 and COX-2 activity w22x. It is, however, very unlikely that it inhibits a putative COX-1 activity in synoviocytes as there was no constitutive production of PGE 2 in these cells and AA did not induce any detectable PGE 2 production in the absence of cytokine. Therefore, as A77 1726-inhibition of PGE 2 production was observed in the presence of 10% FCS in the micromolar range, it might occur in vivo and thus account for part of the beneficial effect of leflunomide in RA. New drugs which specifically inhibit COX-2 but not COX-1 activity have been shown to display anti-inflammatory activities in RA patients w26, 27x. A77 1726 is not a specific inhibitor of COX-2, as it has also been shown to inhibit COX-1 w22x. However, it displays weak inhibitory activity compared with other COX inhibitors with IC 50 values in the micromolar range w22x. However, we cannot rule out the possibility of synergism or an additive effect due to the inhibition of PGE 2 when leflunomide is administered together with other NSAIDs.
Although A77 1726 inhibited MMP-1 production, it did not decrease the level of MMP-1 mRNA, suggesting that the inhibition of MMP-1 production occurred at a post-transcriptional level. This contrasts with data showing that A77 1726 blocks NFkB activation in T cells, MMP-1 promoter containing an NFkBresponsive element w14, 28x. Whether A77 1726 inhibits NFkB nuclear translocation in synoviocytes remains to be determined. A77 1726 might inhibit MMP-1 production because of decreased production of pyrimidine sugars w29x. Indeed, pyrimidine sugars are important in the synthesis of the N-glycans that are present on at least some MMP-1s w30, 31x. Thus, considering its inhibitory effect on DHODH, A77 1726 could decrease the concentration of one or the other of the pyrimidine sugars, triggering misglycosylation of MMP-1, which in turn could hamper its production.
The efficiency of leflunomide in the treatment of RA patients might be due to the fact that it acts at several levels of the inflammatory cascade w32x. Indeed, in addition to the inhibition of production of PGE 2 , MMP-1 and IL-6 in synoviocytes, A77 1726 diminishes the ability of stimulated T cells to induce the production of proinflammatory cytokines in monocytemacrophages w16x, a mechanism highly relevant to chronic inflammation w2, 33-35x. Inhibiting the induction of cytokine production in monocyte-macrophages by A77 1726 in turn lowers the levels of inducers of metalloproteinases, IL-6 and PGE 2 in synoviocytes, and because this affects PGE 2 synthesis directly in the latter cells the production of inflammatory factors is decreased still further. Together, these effects might account for the significant reduction in the rate of disease progression in RA patients treated with leflunomide w36-38x.
In conclusion, this study demonstrates that leflunomide may affect functions of stromal cells involved in tissue destruction in RA. This suggests that leflunomide not only acts on several types of cells involved in the inflammatory cascade but also interferes with different intracellular processes, and may thus display broad efficacy in RA.
